Clinical potential of emerging new agents in hepatitis B

Drugs

Volumn 60, Issue 4, 2000, Pages 701-710

  Farrell, G C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE DERIVATIVE; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; BETA LEVO 2',3' DIDEHYDRO DIDEOXY 5 FLUOROCYTIDINE; BETA LEVO 2',3' DIDEOXY 5 FLUOROCYTIDINE; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; LAMIVUDINE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; HEPATITIS B; HUMAN; IMMUNOMODULATION; REVIEW; SEROCONVERSION; VACCINATION; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0033766631     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060040-00001     Document Type: Review

References (60)

1. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B
2. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
3. Lamivudine: A review of its therapeutic potential in chronic hepatitis B
4. A one-year trial of lamivudine for chronic hepatitis B
5. Lamivudine as initial treatment for chronic hepatitis B in the United States
6. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
7. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
8. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
9. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
10. Three year lamivudine therapy in chronic HBV
11. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B
12. Outcomes of treating chronic hepatitis B with lamivudine
13. Lamivudine reverses severe hepatic decompensation due to replicating hepatitis B infection in patients with cirrhosis
14. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
15. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B vires DNA-positive (precore mutant) chronic hepatitis B: Lamivudine Precore Mutant Study Group
16. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
17. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
18. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials
19. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
20. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B
21. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
22. Acute exacerbation of hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
23. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
24. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immunoglobulin
25. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
26. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wildtype after cessation of therapy
27. Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation?
28. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
29. Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling chronic hepatitis B virus infection before and after transplantation
30. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
31. Combination alphainterferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
32. A randomized controlled trial of thymosin-alpha 1 versus interferon alfa treatment in patients with hepatitis B e antigen, antibody and hepatitis B virus DNA-positive chronic hepatitis B
33. Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: A randomized, controlled trial
34. Interleukin-12: Potential clinical applications in the treatment of chronic viral hepatitis
35. Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B
36. Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B
37. A pilot study of the CY-1899 vaccine in subjects chronically infected with the hepatitis B virus
38. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
39. Perspectives for the treatment of hepatitis B virus infections
40. A preliminary study of lobucavir for chronic hepatitis B
41. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection
42. Efficacy of antiviral drugs in patients with recurrent and de novo hepatitis B infection after liver transplantation
43. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
44. (-)-cis-5-fluoro-1-)2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes
45. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks
46. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
47. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance
48. Adefovir dipivoxil
49. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
50. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
51. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection
52. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection
53. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
54. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
55. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
56. Efficacy of the carbocylic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
57. Two novel antiviral agents, DAPD and L-FMAU, which are active against wild-type and lamivudine-resistant HBV
58. 2',3'-dideoxy-β-L-5fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo
59. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydrobeta-L(-)-5-fluorocytidine
60. 2',3'-Dideoxy-2',3'didehydro-β-L-5-fluorocytidine (β-L-FD4C) exhibits a more potent antiviral effect than lamivudine in chronically WHV infected woodchucks